BioCentury
ARTICLE | Company News

Endovasc, Stanford University deal

July 7, 2003 7:00 AM UTC

The university received a $300,000 milestone from ENDV under a 2002 deal (see BioCentury, Feb. 11, 2002). ENDV's proposed filing of an IND application for a Phase III trial of Angiogenix to treat chro...